Bayer, J&J launch two more late-stage trials of rivaroxaban

03/12/2013 | PharmaTimes (U.K.)

Bayer and Johnson & Johnson are beginning two more late-stage trials of the blood thinner Xarelto, or rivaroxaban, after failing to get the FDA's OK for the treatment of patients with acute coronary syndrome. One trial involves patients with chronic heart failure and significant coronary artery disease. The other will involve patients with nonvalvular atrial fibrillation.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID